Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13265483 | 1.00 | HIF1A (0.61) | HIF1ASLC29A1 | |
| SCHEMBL29502637 | 1.00 | HIF1A (0.61) | HIF1ASLC29A1 | |
| SCHEMBL13265479 | 0.95 | HIF1A (0.65) | HIF1ASLC29A1 | |
| SCHEMBL13265485 | 0.86 | DNPH1 (0.62) | HIF1ASLC29A1 | |
| SCHEMBL5982949 | 0.84 | HIF1A (0.71) | HIF1A | |
| SCHEMBL5982940 | 0.84 | HIF1A (0.71) | HIF1A | |
| SCHEMBL13265431 | 0.84 | HIF1A (0.71) | HIF1A | |
| SCHEMBL13265444 | 0.83 | HIF1A (0.69) | HIF1A | |
| SCHEMBL13239681 | 0.82 | HPGD (0.43) | HIF1ASLC29A1 | |
| SCHEMBL15165603 | 0.82 | HPGD (0.43) | HIF1ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713450-A1 | ENGINEERED CONSTRUCTS WITH CASSETTE ARRANGEMENTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS | Shape Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4677093-A2 | MIRNA FOR CONTROLLING EXPRESSION OF IN VIVO DELIVERY CONSTRUCTS | CREATE Medicines, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4652278-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652279-A2 | COMPOSITIONS FOR MODULATING KRAS EXPRESSION AND USES THEREOF | Molecular Axiom, LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652277-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4638752-A2 | ENGINEERED GUIDE RNAS AND POLYNUCLEOTIDES | Shape Therapeutics Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320491-A1 | CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | EDITAS MEDICINE, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-9410189-B2 | Methods of preventing non-specific reactions of nucleotide sequences | CO-DIAGNOSTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20120045796-A1 | NUCLEIC ACID HOTSTART TECHNOLOGY | CO-DIAGNOSTICS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100317004-A1 | PROBES | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2242761-A1 | METHOD OF MYCOTOXIN DETECTION | Neoventures Biotechnology Inc. (CA) | 2010-10-27 | — | — | EP | disclosed |
| US-7608402-B2 | DNA methylation specific signal amplification | LI WEIWEI | 2009-10-27 | — | — | US | disclosed |
| WO-2009086621-A1 | METHOD OF MYCOTOXIN DETECTION | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2009-07-16 | — | — | WO | disclosed |
| EP-1585835-B1 | Nucleic acid probes and method for detecting a target nucleic acid sequence comprising two or more cis-located nucleic acid regions | DYNAL BIOTECH LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060269916-A1 | Probes | DYNAL BIOTECH INC. | 2006-11-30 | — | — | US | disclosed |
| EP-1585835-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | Dynal Biotech Limited (GB) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004048611-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | DYNAL BIOTECH LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | HIF1A 3888/4885SLC29A1 90/4885 |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | UPF1, RPRD2, NR2E3 | HIF1A 3930/4885SLC29A1 1126/4885 |
| US-20250320491-A1 | CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | TP53, DCAF1, RTF1 | HIF1A 1072/4885SLC29A1 4738/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | HIF1A 1162/4885SLC29A1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.